These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859 [TBL] [Abstract][Full Text] [Related]
3. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498 [TBL] [Abstract][Full Text] [Related]
4. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086 [TBL] [Abstract][Full Text] [Related]
5. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR. Denkberg G; Cohen CJ; Reiter Y J Immunol; 2001 Jul; 167(1):270-6. PubMed ID: 11418659 [TBL] [Abstract][Full Text] [Related]
6. High affinity xenoreactive TCR:MHC interaction recruits CD8 in absence of binding to MHC. Buslepp J; Kerry SE; Loftus D; Frelinger JA; Appella E; Collins EJ J Immunol; 2003 Jan; 170(1):373-83. PubMed ID: 12496422 [TBL] [Abstract][Full Text] [Related]
7. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. Hernández J; Lee PP; Davis MM; Sherman LA J Immunol; 2000 Jan; 164(2):596-602. PubMed ID: 10623800 [TBL] [Abstract][Full Text] [Related]
8. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370 [TBL] [Abstract][Full Text] [Related]
9. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. Dutoit V; Rubio-Godoy V; Doucey MA; Batard P; Liénard D; Rimoldi D; Speiser D; Guillaume P; Cerottini JC; Romero P; Valmori D J Immunol; 2002 Feb; 168(3):1167-71. PubMed ID: 11801651 [TBL] [Abstract][Full Text] [Related]
10. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813 [TBL] [Abstract][Full Text] [Related]
11. Selective induction of high avidity CTL by altering the balance of signals from APC. Oh S; Hodge JW; Ahlers JD; Burke DS; Schlom J; Berzofsky JA J Immunol; 2003 Mar; 170(5):2523-30. PubMed ID: 12594278 [TBL] [Abstract][Full Text] [Related]
12. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. Wooldridge L; Hutchinson SL; Choi EM; Lissina A; Jones E; Mirza F; Dunbar PR; Price DA; Cerundolo V; Sewell AK J Immunol; 2003 Dec; 171(12):6650-60. PubMed ID: 14662868 [TBL] [Abstract][Full Text] [Related]
13. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. Pittet MJ; Rubio-Godoy V; Bioley G; Guillaume P; Batard P; Speiser D; Luescher I; Cerottini JC; Romero P; Zippelius A J Immunol; 2003 Aug; 171(4):1844-9. PubMed ID: 12902485 [TBL] [Abstract][Full Text] [Related]
14. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. Whelan JA; Dunbar PR; Price DA; Purbhoo MA; Lechner F; Ogg GS; Griffiths G; Phillips RE; Cerundolo V; Sewell AK J Immunol; 1999 Oct; 163(8):4342-8. PubMed ID: 10510374 [TBL] [Abstract][Full Text] [Related]
15. Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions. Shen L; Potter TA; Kane KP J Exp Med; 1996 Nov; 184(5):1671-83. PubMed ID: 8920857 [TBL] [Abstract][Full Text] [Related]
16. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. Burrows SR; Kienzle N; Winterhalter A; Bharadwaj M; Altman JD; Brooks A J Immunol; 2000 Dec; 165(11):6229-34. PubMed ID: 11086057 [TBL] [Abstract][Full Text] [Related]
17. Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti-peptide-MHC monoclonal antibody. Chung DH; Belyakov IM; Derby MA; Wang J; Boyd LF; Berzofsky JA; Margulies DH J Immunol; 2001 Jul; 167(2):699-707. PubMed ID: 11441073 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316 [TBL] [Abstract][Full Text] [Related]
19. Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. Nugent CT; Morgan DJ; Biggs JA; Ko A; Pilip IM; Pamer EG; Sherman LA J Immunol; 2000 Jan; 164(1):191-200. PubMed ID: 10605011 [TBL] [Abstract][Full Text] [Related]
20. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Derby MA; Wang J; Margulies DH; Berzofsky JA Int Immunol; 2001 Jun; 13(6):817-24. PubMed ID: 11369710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]